Under this new agreement, Vivos becomes the exclusive U.S. and Canadian distributor of the FDA-approved NR6 Rhinomanometer, a specialized diagnostic device for evaluating nasal breathing and function in dental patients with sleep and breathing issues.
Vivos Therapeutics Inc, a medical technology company focused on developing treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, announced it has entered into an exclusive distribution agreement with GM Instruments Ltd for the distribution of GM Instruments’ NR6 Rhinomanometer, an FDA approved four-phase rhinomanometer available in the U.S. used to calculate nasal airway resistance by measuring nasal flow and the pressure producing that flow.
Under this new agreement, Vivos becomes the exclusive U.S. and Canadian distributor of this specialized diagnostic equipment for evaluating nasal breathing and function in dental patients with sleep and breathing issues. According to Vivos, the objective measurement of nasal breathing can be an essential data point in determining the appropriate breathing and sleep issue treatment pathway as well as a predictor of potential Continuous Positive Airway Pressure (CPAP) intolerance or other treatment failure.
“With this new agreement, every U.S. or Canadian dentist who wishes to evaluate the breathing function of a patient will need to engage with Vivos for this diagnostic equipment. We expect this will provide Vivos an immediate new revenue stream as well as a substantial competitive advantage and opportunity to present Vivos’ proprietary oral appliance technology to a wider audience,” said Vivos Chairman and CEO, Kirk Huntsman.
Based in the United Kingdom, GM Instruments is a global manufacturer and distributor of diagnostic technology for assessing nasal and respiratory flow and function. The GM Instruments’ NR6 Rhinomanometer reportedly offers a quick non-invasive test to measure the function of the nose during active breathing. These test results are being used by Vivos-trained dentists and others to measure outcomes of improvement for pre-, mid-, and post-treatment of patients undergoing a variety of treatment modalities. Additionally, GM Instruments products are planned for use as part of research protocols to improve and support the outcomes of Vivos products and methods for OSA diagnosis and treatment.
The NR6 Rhinomanometer reportedly is used across the world in specialties that address nasal obstruction and nasal flow limitations. According to Vivos, recent studies show the impact of nasal resistance on the distribution of apneas and hypopneas in OSA. Such studies reportedly have also highlighted the use of rhinomanometry in patient selection for probable success or failure with CPAP and oral appliance therapy. The research findings emphasize the importance of measuring nasal flow and transnasal pressure in reducing disease and improving breathing.
In a press release from Vivos, Dr Martha Cortes, a Vivos-trained dentist in New York City who has used Vivos technology to treat over 1,600 patients in her Manhattan practice, emphasized the importance of having NR6 rhinomanometry available to her patients, stating, “For the first time, I have a dynamic and objective measurement that I can take multiple times throughout treatment to measure and demonstrate the impact that Vivos therapy may have on the nasal cavity which could affect the upper airway. As I frequently remind my patients and colleagues, it is only an opinion without data.”
“Many medical problems such as OSA, overall lung function, and even spinal and posture issues are related to nasal resistance and poor breathing, and our breathing is disrupted before our sleep is disrupted. With this strong collaboration with Vivos, we believe we have the opportunity to change the standard of care for OSA to improve patient outcomes and manage their health with better testing and assessments,” said Dr Karen Parker Davidson, RN, vice president of sales for GM-Instruments, North America.